Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

References

• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16, 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene26, 3603–3613 (2007).
   PubMed Web of Science ®Google Scholar
• Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol.149, 3–13 (2010).
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin. Hematol.47, 115–123 (2010).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum.54, 613–620 (2006).
   PubMed Web of Science ®Google Scholar
• Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy – rare but there! Leuk. Lymphoma50, 1083–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br. J. Haematol.121, 913–918 (2003).
   PubMed Web of Science ®Google Scholar
• Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant33, 921–923 (2004).
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Hakim F, Kim HK et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood106, 795–802 (2005).
   PubMed Web of Science ®Google Scholar
• Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol.18, 364–369 (2007).
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk. Lymphoma47, 1013–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Fukuno K, Tsurumi H, Ando N et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int. J. Hematol.84, 242–247 (2006).
   PubMed Web of Science ®Google Scholar
• Tesfa D, Gelius T, Sander B et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med. Oncol.25, 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am. J. Hematol.84, 414–417 (2009).
   PubMed Web of Science ®Google Scholar
• Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica89, 361–363 (2004).
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Kohda K, Konuma Y et al. Late-onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation. Intern. Med.48, 57–60 (2009).
   PubMed Web of Science ®Google Scholar
• Marotte H, Paintaud G, Watier H, Miossec P. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann. Rheum. Dis.67, 893–894 (2008).
   PubMed Web of Science ®Google Scholar
• Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br. J. Dermatol.157, 1271–1273 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.60, 2156–2168 (2009).
   PubMed Web of Science ®Google Scholar
• Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol.5, 1359–1362 (2010).
   PubMedGoogle Scholar
• Tesfa D, Ajeganova S, Hagglund H et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum.63, 2209–2214 (2011).
   PubMed Web of Science ®Google Scholar
• Andersohn F, Konzen C, Garbe E. Systemic review: agranulocytosis induced by nonchemotherpy drugs. Ann. Intern. Med.146, 657–665 (2007).
   PubMed Web of Science ®Google Scholar
• Mosyagin I, Cascorbi I, Schaub R et al. Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? J. Clin. Psychopharmacol.25, 435–440 (2005).
   PubMed Web of Science ®Google Scholar
• Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am. J. Hematol.84, 428–434 (2009).
   PubMed Web of Science ®Google Scholar
• Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcγRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol.28, 279–284 (2010).
   PubMed Web of Science ®Google Scholar
• Li SC, Chen YC, Evens AM et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am. J. Hematol.85, 810–812 (2010).
   PubMed Web of Science ®Google Scholar
• Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N. Engl. J. Med.348, 2691–2694; discussion 2691–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk. Res.26, 597–600 (2002).
   PubMed Web of Science ®Google Scholar
• Coakley G, Iqbal M, Brooks D, Panayi GS, Lanchbury JS. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications of felty’s and large granular lymphocyte syndromed. Arthritis Rheum.43, 834–843 (2000).
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T et al. Chronic neutropenia mediated by fas ligand. Blood95, 3219–3222 (2000).
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Papadaki T, Pontikoglou C et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia22, 1446–1449 (2008).
   PubMed Web of Science ®Google Scholar
• Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood102, 1557–1558 (2003).
   PubMed Web of Science ®Google Scholar
• Rezvany MR, Jeddi-Tehrani M, Wigzell H, Osterborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood101, 1063–1070 (2003).
   PubMed Web of Science ®Google Scholar
• Terrier B, Ittah M, Tourneur L et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica92, e20–e3 (2007).
   PubMed Web of Science ®Google Scholar
• Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J. Exp. Med.201, 1771–1780 (2005).
   PubMed Web of Science ®Google Scholar
• Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin. Hematol.43, 185–195 (2006).
   Google Scholar
• Carlsson G, Andersson M, Putsep K et al. Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia. Acta Paediatr.95, 1526–1532 (2006).
   PubMedGoogle Scholar
• Carlsson G, Andersson M, Putsep K et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr.96, 813–819 (2006).
   Google Scholar
• Carlsson G, Aprikyan AG, Tehranchi R et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome C, and excessive apoptosis of myeloid progenitor cells. Blood103, 3355–3361 (2004).
   PubMedGoogle Scholar
• Anolik JH, Campbell D, Felgar RE et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum.48, 455–459 (2003).
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Kato H, Yamamoto K, Matsuo K et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann. Oncol.21, 1699–1705 (2010).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD 20 monoclonal antibody therapy in non-Hodgkin`s lymphoma : safety and efficay of re-treatment. J. Clin. Oncol.18, 3135–3143 (2000).
   PubMed Web of Science ®Google Scholar
• Van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction : results of a prospective randomized Phase 3 intergroup trial. Blood108, 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantel cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study group (GLSG). Blood108, 4003–4008 (2006).
   PubMed Web of Science ®Google Scholar
• Gottenberg J, Ravaud P, Bardin T et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry. Arthritis Rheum.62, 2625–2632 (2010).
   PubMed Web of Science ®Google Scholar